List view / Grid view
13 March 2014 | By Novartis
Novartis has announced that Australia has joined the growing number of countries where following licensure, Bexsero® has received a clinical recommendation...
7 March 2014 | By Novartis
Novartis announced that a pivotal Phase III trial of Jakavi® (ruxolitinib) compared to best available therapy has met its primary endpoint of maintaining hematocrit control...
6 March 2014 | By Novartis
Novartis announced that the European Commission has approved the use of Xolair® as an add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent patients...
28 February 2014 | By Novartis
Novartis joins the global rare disease community in recognition of Rare Disease Day by calling for a global exchange of ideas to deepen the understanding of rare diseases and help address a significant unmet medical need...
26 February 2014 | By Novartis
Novartis announced additional steps to extend its leadership in clinical trial data transparency...
25 February 2014 | By Novartis
A strong majority of Novartis shareholders today followed the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting...
24 February 2014 | By Novartis
Novartis announced that its meningococcal serogroup B vaccine, Bexsero®, will be used as part of a vaccination program at the University of California Santa Barbara and will end on March 7...
21 February 2014 | By Novartis
Lucentis® (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: the treatment of patients with diabetic macular edema, a leading cause of vision loss among patients with diabetes...
19 February 2014 | By Novartis
Novartis announced that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment...
17 February 2014 | By Novartis
Novartis announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals Inc...
27 January 2014 | By Novartis
Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100...
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xolair®...
12 January 2014 | By Novartis
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect...
9 December 2013 | By Novartis
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials...
